Combination therapy with a novel agent, albuvirtide, in hospitalised AIDs patients

Combination therapy with a novel agent, albuvirtide, in hospitalised AIDS patients

Delayed therapy start and antiretroviral therapy (ART) resistance are two common issues affecting up to 33% and 17% of patients infected with human immunodeficiency virus (HIV), respectively. These patients commonly present with higher viral loads, lower CD4 T-cell count, and complications such as infections requiring acute treatment. For those patients presenting with acquired immunodeficiency syndrome (AIDS) or those who have breakthrough HIV, and who present with opportunistic infections and comorbidities requiring hospitalisation, ART treatments are limited.

Gender-related differences in safety

Gender-related differences in safety after switching to BIC/TAF/FTC

Human immunodeficiency virus (HIV), one of most serious public health challenges in the world, has already affected approximately 37.6 million people across the globe in 2020 and new infections in 2020 are estimated to be 1.5 million. Bictegravir/ Emtricitabine/ tenofovir (BIC/TAF/FTC) is a fixed-dose combination tablet consisting of an integrase inhibitor and two nucleoside reverse transcriptase inhibitors for the treatment of HIV infection. This HIV medication was approved by the United States Food and Drug Administration (USFDA) in 2018 due to the excellent efficacy outcomes in clinical trials. Real-world safety data of BIC/TAF/FTC was presented at the 18th European AIDS Conference in 2021 and summarised below.

interim-results-of-a-Phase-2b-3-trial-investigating-a-long-acting-injectable-of-cabotegravir-for-pre-exposure-prophylaxis-of-HIV

Interim results of a Phase 2b/3 trial investigating a long-acting injectable of cabotegravir for pre-exposure prophylaxis of HIV

There is no excerpt because this is a protected post.

comparison-of-the-metabolic-changes-from-the-tango-trial-a-post-hoc-analysis

Comparison of the metabolic changes from the TANGO trial: a post-hoc analysis

There is no excerpt because this is a protected post.

Carboplatin plus paclitaxel to be the new standard of care for anal cancer

Carboplatin plus paclitaxel to be the new standard of care for anal cancer

The incidence of anal cancer has been increasing over the past decade, but currently still constitutes 0.5% of all cancer diagnoses in the United States. When the cancer has metastasised, prognosis remains poor, with relative 5-year survival rates of approximately 30%. The current standard of care for metastatic anal cancer is cisplatin-based chemotherapy combined with 5-fluorouracil (5-FU). However, no randomised clinical trial investigating the optimal chemotherapy regimen for this disease has been conducted. The InterAAct trial was launched to investigate cisplatin plus FU against carboplatin plus paclitaxel in advanced anal cancers, and full results were recently published in the Journal of Clinical Oncology.